Tianjin Medical University Cancer Institute and Hospital: all 490 studies

Page 2 of 5. Open to participants first (289), then studies with results posted, then the rest; newest registration first within each.

• A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)Not yet recruitingNCT07324876
• A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast CanceRecruitingNCT07321015Phase 2
• Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in ChildrenRecruitingNCT07318831Phase 2
• SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyNot yet recruitingNCT07307287Phase 2
• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesRecruitingNCT07304739Phase 2
• Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic CancerNot yet recruitingNCT07302841Phase 4
• Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal CancerRecruitingNCT07281157Phase 2
• Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic TherapyNot yet recruitingNCT07277972Phase 2
• A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07272291Phase 2
• Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder CancerNot yet recruitingNCT07263360Phase 2
• A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer PatientsNot yet recruitingNCT07254416Phase 4
• Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingNCT07246330Phase 3
• Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast CancerNot yet recruitingNCT07246317Phase 2
• Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07244926Phase 2
• Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBCNot yet recruitingNCT07244874Phase 2
• Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT AssessmentNot yet recruitingNCT07206264Phase 2
• The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric CancerRecruitingNCT07183150
• Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant ImmunotherapyNot yet recruitingNCT07179445
• Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT07172412Phase 2
• Personalized SBRT in Early-Stage Peripheral NSCLCEnrolling by invitationNCT07167459Phase 2
• Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer PatientsNot yet recruitingNCT07162519Not applicable
• dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction ChemoimmunotherapyRecruitingNCT07162506Phase 2
• Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07157306Phase 2
• Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast CancerNot yet recruitingNCT07153965Phase 2
• Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)RecruitingNCT07147426Phase 2
• QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody TherapyNot yet recruitingNCT07141186Phase 2
• Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast CancerNot yet recruitingNCT07139470Phase 1/2
• A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)Not yet recruitingNCT07119931Phase 2
• RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple MyelomaNot yet recruitingNCT07114432Phase 1
• Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular CarcinomaRecruitingNCT07099274Phase 2
• Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical CancerRecruitingNCT07092696Phase 2
• Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line TreatmentNot yet recruitingNCT07078305Phase 2
• The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world StudyNot yet recruitingNCT07078292
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid TumorsRecruitingNCT07058948Phase 2
• Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical StudyRecruitingNCT07047560Phase 2
• Chemoradiation Plus Iparomlimab Consolidation in Older With ESCCRecruitingNCT07038629Phase 2
• A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast CancerNot yet recruitingNCT07035353
• Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric CancerNot yet recruitingNCT07033143Phase 2
• A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FLNot yet recruitingNCT07031700Phase 2
• Supermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb LymphedemaNot yet recruitingNCT07026292Not applicable
• A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin PaclitaxelRecruitingNCT07019233Not applicable
• FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular CarcinomaRecruitingNCT07012798Phase 2
• BR Combined With OR in Treatment-naïve Marginal Zone LymphomaNot yet recruitingNCT07008053Phase 2
• Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07005583Phase 2
• A Multicenter Randomized Controlled Clinical Trial of the Impact of Minimally Invasive Abdominal Surgery Esophageal Pressure Monitoring Guided Individualized PEEP on Postoperative Pulmonary Complications in Obese PatientsNot yet recruitingNCT06996288Not applicable
• Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract MalignanciesNot yet recruitingNCT06993025Phase 2
• SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant AscitesNot yet recruitingNCT06991478Phase 1/2
• A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid TumorRecruitingNCT06954558Phase 1
• QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic CancerRecruitingNCT06951997Phase 2
• A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic CancerRecruitingNCT06944106Phase 2
• Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLCRecruitingNCT06939127Phase 2
• AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic CancerNot yet recruitingNCT06938503Phase 2
• QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial CancerRecruitingNCT06917092Phase 2
• Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction TherapyNot yet recruitingNCT06914050Phase 2
• A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesRecruitingNCT06914037Phase 1
• Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLCNot yet recruitingNCT06890182Phase 2
• A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast CancerRecruitingNCT06878625Phase 2
• Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular CarcinomaNot yet recruitingNCT06867432Phase 2
• Second-line Immunotherapy for ES-SCLCRecruitingNCT06853678Not applicable
• Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder CancerRecruitingNCT06852287Phase 2
• Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain MetastasesNot yet recruitingNCT06852001Not applicable
• The Importance of Thymus Anatomy to the Radical Resection of Thyroid Cancer Surgery and the Protection of Parathyroid FunctionNot yet recruitingNCT06851260Not applicable
• Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal CancerNot yet recruitingNCT06814158Phase 2
• Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung CancerRecruitingNCT06775678Phase 2
• Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver CancerRecruitingNCT06766643Phase 2
• A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic CancerRecruitingNCT06760364Phase 1
• A Clinical Study of CHT101 in CD70-Positive Advanced Solid TumorsRecruitingNCT06730659Phase 1
• Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk FactorsRecruitingNCT06727617Phase 2
• Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic CholangiocarcinomaRecruitingNCT06721286Phase 2
• A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid TumorsRecruitingNCT06717022Not applicable
• A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors.Not yet recruitingNCT06717009Not applicable
• Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT06704620Phase 3
• Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular LymphomaRecruitingNCT06704555Phase 2
• The Effect of Serum Ferritin in irAERecruitingNCT06702566Not applicable
• Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer PatientsNot yet recruitingNCT06697990Phase 2
• Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingNCT06656559Phase 2
• Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation ProceduresNot yet recruitingNCT06581107Not applicable
• Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLRecruitingNCT06570447Phase 2
• Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 OverexpressionRecruitingNCT06560528Phase 2
• Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingNCT06512467Phase 2
• A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)RecruitingNCT06506292Phase 2
• Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic TherapyRecruitingNCT06498154Phase 2
• Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction CancerRecruitingNCT06496789Phase 2
• The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 PositiveNot yet recruitingNCT06495541Not applicable
• Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast CancerRecruitingNCT06495515Phase 2
• AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT06489197Phase 2
• TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant TumorsRecruitingNCT06487663Not applicable
• Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast CancerNot yet recruitingNCT06483386Phase 2
• Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular LymphomaNot yet recruitingNCT06474481Phase 2
• AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDACRecruitingNCT06472037Phase 2
• Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL PatientsRecruitingNCT06463691Phase 2
• Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic CancerRecruitingNCT06454448Phase 1/2
• Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric CancerNot yet recruitingNCT06454435Phase 2
• Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.RecruitingNCT06452602Phase 2
• Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity ResultsNot yet recruitingNCT06438055Not applicable
• CMOEP in the Treatment of Untreated Peripheral T-cell LymphomaRecruitingNCT06433362Phase 2
• The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective StudyRecruitingNCT06417567
• Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment FailureRecruitingNCT06413017Phase 2
• Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic CancerNot yet recruitingNCT06409429Phase 2/3
• Nimotuzumab Plus AG in Pancreatic Cancer With Liver MetastasisRecruitingNCT06405685Phase 2

← Tianjin Medical University Cancer Institute and Hospital overview and focus areas